Here are relevant reports on : cancer-immunotherapy-market
-
Global Colorectal Cancer Market (2010-2015)
2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Global Breast Cancer Drugs Market
There are about one million new cases of breast cancer every year. Breast cancer accounts for about 10% of world wide cancer. There has been significant increase in awareness levels with respect to impact on survival rates incase of early diagnosis. Therefore, opening novel opportunities for breast cancer drugs market.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Renal Cancer Drugs Market by therapy (targeted therapy, chemotherapy, and immunotherapy), drug class (anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors), indication (renal cell carcinoma, urothelial carcinoma, and others), distribution channel (hospitals, specialty & retail pharmacies and others), and region (North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa) – global forecasts to 2027
The renal cancer drugs market is projected to reach USD 8 billion by 2027 from USD 6 billion in 2022, at a CAGR of 6% during the forecast period.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Flow Cytometry Market by Technology (Cell-based, Bead-Based), Product & Service (Analyzer, Sorter, Consumables (Antibodies, Assays, Kits), Software), Application (Research (Stem Cell), Clinical (Cancer)), End User (Hospital) - Global Forecast to 2033
The global flow cytometry market, valued at US$4.87 billion in 2024, stood at US$5.06 billion in 2025 and is projected to advance at a resilient CAGR of 8.7% from 2025 to 2033, culminating in a forecasted valuation of US$9.85 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030
The North America biomarkers Market, valued at US$23.35 billion in 2024, stood at US$25.13 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$45.25 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Real World Evidence Solutions Market by Component (Datasets (Claims, Clinical, Pharmacy, Genomics), Application (Drug/Device Development (Cancer, Cardio, Neuro), Reimbursement), End User (Pharma, Medtech, Payers, Provider), Region - Global Forecast to 2030
The global real world evidence solutions market, valued at US$4.74 billion in 2024, stood at US$5.42 billion in 2025 and is projected to advance at a resilient CAGR of 14.8% from 2025 to 2030, culminating in a forecasted valuation of US$10.8 billion by the end of the period.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
